MedPath

Medtronic's Affera System Receives FDA Approval for Atrial Fibrillation and Flutter Treatment

• Medtronic's Affera mapping and ablation system, featuring the Sphere-9 catheter, has been approved by the FDA. • The Affera system is designed for treating persistent atrial fibrillation and atrial flutter. • Medtronic now offers two pulsed field ablation technologies for atrial fibrillation, including the previously approved PulseSelect system. • The Affera system also addresses radiofrequency ablation of cavotricuspid isthmus-dependent atrial flutter, reducing thromboembolic event risks.

Medtronic has announced FDA approval for its Affera mapping and ablation system, which includes the Sphere-9 catheter, marking a significant advancement in the treatment of atrial fibrillation and atrial flutter. This approval positions Medtronic as the first and only company offering two pulsed field ablation (PFA) technologies for patients with persistent atrial fibrillation, following the approval of the PulseSelect PFA system in December 2023.

Addressing Atrial Fibrillation and Flutter

The Affera system is designed to treat both persistent atrial fibrillation and cavotricuspid isthmus-dependent atrial flutter. Atrial flutter, the most common macro-reentrant atrial tachycardia, can lead to thromboembolic events and heart failure if left untreated. The Affera system provides radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter, addressing this critical need.

Significance of the Approval

This FDA approval expands the treatment options available to patients suffering from these common heart rhythm disorders. With two PFA technologies now available, physicians have greater flexibility in tailoring treatment strategies to individual patient needs. The Affera system's ability to map and ablate cardiac tissue offers a comprehensive solution for managing complex arrhythmias.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Medtronic's Affera System with Sphere-9 Catheter Receives FDA Approval for Atrial Fibrillation Treatment

The FDA has approved Medtronic's Affera Mapping and Ablation System with Sphere-9 Catheter for treating persistent atrial fibrillation and atrial flutter.
The Sphere-9 catheter offers both pulsed field and radiofrequency ablation options, integrated with the Affera mapping system for enhanced workflow.

FDA Approves Medtronic's Affera System, a Dual-Energy Ablation Technology for Atrial Fibrillation

The FDA has approved Medtronic's Affera system, a dual-energy (pulsed-field and radiofrequency) ablation system, for treating atrial fibrillation (AF).
The Affera system's approval was based on the SPHERE Per-AF trial, which demonstrated noninferior efficacy and safety compared to radiofrequency ablation.

Medtronic's Affera System with Sphere-9 Catheter Approved by FDA for Atrial Fibrillation Treatment

The FDA has approved Medtronic's Affera Mapping and Ablation System with Sphere-9 catheter for treating persistent atrial fibrillation and atrial flutter.
The Sphere-9 catheter offers both pulsed field and radiofrequency ablation options, integrated with the Affera mapping system for enhanced workflow.

Medtronic's Affera System Receives FDA Approval for Persistent Atrial Fibrillation Treatment

Medtronic's Affera mapping and ablation system secured FDA approval for treating persistent atrial fibrillation (AFib).
The Affera system uniquely combines mapping technology with radiofrequency (RF) and pulsed field ablation (PFA) capabilities in a single catheter.

Medtronic's Affera System Receives FDA Approval for Persistent Atrial Fibrillation Treatment

Medtronic's Affera mapping and ablation system secured FDA approval for treating persistent atrial fibrillation (AFib) by combining mapping with radiofrequency (RF) and pulsed field ablation (PFA).
The Affera system's Sphere-9 catheter allows switching between RF and PF energy, integrated with mapping technology, potentially impacting point-by-point ablation procedures.

Medtronic's Affera System with Sphere-9 Catheter Approved by FDA for Atrial Fibrillation Treatment

The FDA has approved Medtronic's Affera mapping and ablation system with the Sphere-9 Catheter for treating persistent atrial fibrillation and atrial flutter.
The Affera system is the first to offer both pulsed-field and radiofrequency ablation, enhancing treatment flexibility for AFib patients.

Medtronic's Affera System with Sphere-9 Catheter Receives FDA Approval for Atrial Fibrillation Treatment

Medtronic's Affera mapping and ablation system with the Sphere-9 catheter has gained FDA approval for treating persistent atrial fibrillation (AFib) and atrial flutter.
The system offers both pulsed field ablation (PFA) and radiofrequency (RF) ablation, providing physicians with versatile treatment options for cardiac arrhythmias.

Medtronic's Affera System with Sphere-9 Catheter Receives FDA Approval for Atrial Fibrillation Treatment

Medtronic's Affera Mapping and Ablation System with Sphere-9 Catheter gains FDA approval for treating persistent atrial fibrillation and atrial flutter.
The system is the first to offer both pulsed field and radiofrequency ablation, providing physicians with versatile treatment options.

Medtronic's Affera System with Sphere-9 Catheter Receives FDA Approval for Atrial Fibrillation Treatment

Medtronic's Affera Mapping and Ablation System with Sphere-9 Catheter gains FDA approval for treating persistent atrial fibrillation and atrial flutter.
The Sphere-9 catheter offers both pulsed field and radiofrequency ablation options, enhancing workflow efficiency and treatment flexibility for physicians.

Medtronic's Affera System Receives FDA Approval for Atrial Fibrillation and Flutter Treatment

Medtronic's Affera Mapping and Ablation System with Sphere-9 Catheter gains FDA approval for treating persistent atrial fibrillation and atrial flutter.
The system is the first to offer both pulsed field and radiofrequency ablation, enhancing treatment flexibility for electrophysiologists.

Reference News

[1]
Medtronic Gets FDA Approval for Affera Technology | Morningstar
morningstar.com · Oct 25, 2024

Medtronic's Affera mapping and ablation system with sphere-9 catheter gets FDA approval, making it the first company wit...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy